Although various articles have examined the roles of SIRT1 in suppressing the promotion of autoimmune diseases, many studies described in this review support the hypothesis that SIRT1 represents a possible biomarker of relapses and a potential target for therapeutic intervention in multiple Ads, including SLE, RA, IBD, MS, regardless of whether it functions as an activator or inhibitor. This evidence concerns the gene SIRT1 and myeloid sarcoma.